Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spirit Scientific CoROCO:7790 -3.93%26 EV-to-EBIT is 100.39 as of Sep. 08, 2026, which is 16% below its 10-year median of 119.13. GuruFocus rates ROCO:7790 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 365 Biotechnology companies, Spirit Scientific Co ranks worse than 92.05% on this metric.
Spirit Scientific Co (ROCO:7790) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Spirit Scientific Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$791.8 Mil.
Spirit Scientific Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spirit Scientific Co EV-to-EBIT Related Terms
Spirit Scientific Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Spirit Scientific Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7790 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Spirit Scientific Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spirit Scientific Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spirit Scientific Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Spirit Scientific Co's EV-to-EBIT falls into.
Spirit Scientific Co's current Enterprise Value is NT$788.4 Mil.
Spirit Scientific Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spirit Scientific Co (ROCO:7790) has a EV-to-EBIT of 100.39 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spirit Scientific Co and its competitors. This is 16% below median its historical median of 119.13. Over the past decade, Spirit Scientific Co's EV-to-EBIT has ranged from 57.67 to 1,575.70. According to the industry distribution chart, Spirit Scientific Co ranks #336 out of 365 companies in the Biotechnology industry, placing it in the top 92.1%.
Is Spirit Scientific Co's EV-to-EBIT too high?
Spirit Scientific Co's current EV-to-EBIT of 100.39 is 16% below median its 10-year median of 119.13. Over the past 10 years, this metric has ranged from a low of 57.67 to a high of 1,575.70. The Biotechnology industry median EV-to-EBIT is 15.65. Spirit Scientific Co's value of 100.39 is 541.5% above this industry median. Based on the distribution chart, Spirit Scientific Co ranks #336 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spirit Scientific Co has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spirit Scientific Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spirit Scientific Co ranks #336 out of 365 companies for EV-to-EBIT. This places Spirit Scientific Co in the lower half of its industry. The industry median EV-to-EBIT is 15.65. Spirit Scientific Co's value of 100.39 is 541.5% above this benchmark. Historically, Spirit Scientific Co's own EV-to-EBIT has ranged from 57.67 to 1,575.70 over the past decade. While the company's 10-year median is 119.13 vs. the industry median of 15.65, Spirit Scientific Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.65, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spirit Scientific Co's current EV-to-EBIT of 100.39 is 541.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spirit Scientific Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spirit Scientific Co's current EV-to-EBIT is 100.39, which is 16% below median its own 10-year median of 119.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spirit Scientific Co stock overvalued right now?
Spirit Scientific Co (ROCO:7790) has a current EV-to-EBIT of 100.39. The current EV-to-EBIT is 100.39, which is 16% below median its 10-year median of 119.13 and 541.5% above the Biotechnology industry median of 15.65. Spirit Scientific Co's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Spirit Scientific Co (ROCO:7790), the current EV-to-EBIT is 100.39 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spirit Scientific Co Ltd is engaged in precision regenerative medicine, specializing in platelet cryocrystallization technology and Bio Material Lyophilized Technology (BMLT). The company provides solutions for extracting high-concentration platelet growth factors, enabling safe, flexible, and long-term storage therapies. Spirit Biotech delivers cutting-edge autologous healing reagent preparation services, along with OEM and ODM models. With a focus on unmet medical needs, the company transforms patented technologies into scalable solutions, advancing the future of regenerative healthcare.
26GF Score
Get the complete analysis for ROCO:7790
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7790 has been successfully added to your 
